← All stocks

Taysha Gene Therapies, Inc.

TSHA Net buying

CIK 0001806310 #2058 in the set updated 18 Sep 2026

Bought (120 mo)

$27.01M

out of their own pocket, the only kind of buying there is

Sold (120 mo)

$10.78M

$1.32M on a plan · $4.18M straight out of an exercise

Sold at will

$5.28M

36 of 43 sales

Net

+$16.23M

+$21.73M against sales at will

By person

10 insiders · 66 transactions

53.4×

Sean Nolan holds 53.4 times base salary in stock. $34.54M of shares against $645.84K in salary for 2025.

Salary from the company's own proxy. The shares are what Sean Nolan last reported holding, valued at $6.24, the price Common Stock was last bought or sold at on the open market here, on 10 Jul 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Manning Paul B

10% owner

$25.15M (13)

—

+$25.15M

6,195,139

1.90%

$38.66M

—

Nagendran Sukumar

President and Head of R&D

$83.50K (2)

$6.13M (9) scheduled

−$6.05M

936,410

0.2874%

$5.84M

—

PRASAD SUYASH

CMO and Head of R&D

—

$2.02M (12)

−$2.02M

530,589

0.1628%

$3.31M

—

Alam Kamran

CHIEF FINANCIAL OFFICER

—

$1.40M (14)

−$1.40M

1,442,131

0.4426%

$9.00M

—

Stalfort John A III

Director

$700.00K (2)

—

+$700.00K

2,060,849

0.6325%

$12.86M

+86.4%

Nolan Sean P.

Chief Executive Officer

$426.15K (2)

$840.20K (2)

−$414.05K

5,534,903

1.70%

$34.54M

+407.3%

Session R.A. II

10% owner

$529.10K (2)

$388.73K (6)

+$140.37K

8,871,747

2.72%

$55.36M

−2.8%

Donenberg Phillip B.

Director

$123.34K (2)

—

+$123.34K

241,289

0.0741%

$1.51M

—

Long Alison S

Director

—

127,178

0.0390%

$793.59K

—

Sepp-Lorenzino Laura

Director

—

127,178

0.0390%

$793.59K

—

Individual transactions

Insider

Date

Role

Action

Price

Amount

Nagendran Sukumar

10 Jul 2026

President and Head of R&D

Sold on a plan

200,000

$6.24

$1.25M

Alam Kamran

24 Aug 2023

Chief Financial Officer

Sold on a plan

33,000

$2.33

$76.89K

Show all 66 transactions →

What was left out

Form 4 filings counted 106

Amendments (4/A) skipped 1

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 2

Sales straight out of an exercise 5

Sales at will 36

Transactions with no price 0

Shares from compensation/vesting 14,986,465

Sales filed before the plan box existed 21

History held since 25 Sep 2020